Maurie Markman, MD


May 24, 2011

This feature requires the newest version of Flash. You can download it here.

Hello. I'm Dr. Maurie Markman from Cancer Treatment Centers of America. I am doing this video to encourage you to attend some of the very interesting sessions dealing with gynecologic cancers that are going to be presented at [the 2011 annual meeting of the American Society of Clinical Oncology] in the next week and a half. Some of the press releases that came from ASCO® about these sessions are very provocative and other papers now listed in the abstracts are also very interesting.

We are all waiting with great interest for the results of a randomized controlled trial that looked at the combination of bevacizumab with carboplatin and gemcitabine in patients who had previously received chemotherapy for ovarian cancer. A very interesting, provocative study that looked specifically at the combination of AZD-2281 (olaparib) used as a maintenance strategy in ovarian cancer was reported by ASCO® as being a positive trial. It will be very interesting to discuss this.

Very interesting data are coming out of the PLCO [Prostate, Lung, Colorectal, Ovarian cancer] randomized controlled trial, which are reported to be negative. In fact, in the discussion there was even some evidence of harm with respect to evaluation for ovarian cancer in the screening setting.

A number of important studies looked at molecular markers and also some very provocative data will be presented on a number of very exciting drugs in the gynecologic malignancy arena, some phase 2 data with provocative response rates and time to progression. This is going to be a very interesting year in terms of the presentations and some very exciting early data.

I would encourage you to go to the oral sessions as well as to the poster discussion section and the poster session. It looks like some very important drugs and very important trials will be presented, both definitive as well as early-stage trials, so I would encourage you to participate in these sessions. Thank you.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: